RxDoctor Payments Data

Elizabeth Vorhees

Nurse Practitioner · Chicago, ILNPI 1194399071

Payments from drug & device makers

$1,904in general payments, 2019–2025

Across 76 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$635
  • Boston Scientific$253
  • Kestra Medical Technology Services, Inc.$226
  • Boehringer Ingelheim$193
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$144
  • Novartis$98
  • plus $356 from 9 others

What the payments were for

  • Food & beverage$1,904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,904 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$87,480
Medicare patients
397
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten40$324,021
JardianceEmpagliflozin37$27,018
EntrestoSacubitril/Valsartan18$12,414
EliquisApixaban14$11,815
Bumetanide103$3,613
Metoprolol Succinate74$971
Torsemide59$904
Spironolactone93$659
Potassium Chloride48$444
Losartan Potassium40$343
Furosemide92$302
Hydralazine Hcl14$225
Isosorbide Mononitrate ErIsosorbide Mononitrate22$199
Carvedilol17$106
Metolazone14$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$635$324,02140 claims
Boehringer IngelheimJardiance$193$27,01837 claims
NovartisEntresto$98$12,41418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →